Emyria Limited (ASX:EMD)


right-arrow Created with Sketch. 0.015 (4.17%)
MCAP $103.1M
Last trade 15.56pm 28/01/2022 20mins delayed

Latest Announcements

28/01/2022EMDEmyria Limited
28/01/2022EMDEmyria Limited
28/01/2022 Price SensitivePSEMDEmyria Limited
21/01/2022EMDEmyria Limited
21/01/2022EMDEmyria Limited
20/01/2022 Price SensitivePSEMDEmyria Limited
31/12/2021EMDEmyria Limited
30/12/2021EMDEmyria Limited

Company Overview

Emyria Limited is an Australia-based healthcare technology and clinical research company. The Company provides care for its patients through its clinics gathering real-world-evidence (RWE) insights in relation to therapies, such as cannabinoid-based medicines and drug development. Its evidence-based drug development program (EMD-003) is focused on mental health and EMD-004 is focused on irritable bowel syndrome (IBS). The Company’s subsidiaries include Emyria Clinical Network Pty Ltd and Openly Care Inc.

EMD in the news

Emyria (EMD) is set to begin phase one clinical trials of its…
Emyria (EMD) appoints Sixty Two Capital as its corporate advisor to support…
Emyria (EMD) signs a letter of intent with US biomedical device company…
Emyria (EMD) reports positive bioanalytical results of its ultra-pure CBD formulationIn a…

Search Previous Announcements